AAP
ADPT icon

Aristotle Atlantic Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Aristotle Atlantic Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4M Buy
1,838,513
+124,167
+7% +$1.9M 1.64% 17
2026
Q1 		$23.8M Sell
1,714,346
-128,098
-7% -$2.04M 1.11% 31
2025
Q4 		$29.9M Sell
1,842,444
-1,284,275
-41% -$21M 1.37% 22
2025
Q3 		$46.8M Buy
3,126,719
+247,402
+9% +$3.01M 1.36% 20
2025
Q2 		$33.5M Sell
2,879,317
-61,895
-2% -$562K 1.02% 29
2025
Q1 		$21.9M Buy
2,941,212
+54,510
+2% +$419K 0.74% 41
2024
Q4 		$17.3M Sell
2,886,702
-114,499
-4% -$631K 0.54% 51
2024
Q3 		$15.4M Buy
3,001,201
+27,013
+0.9% +$118K 0.48% 51
2024
Q2 		$10.8M Sell
2,974,188
-18,375
-0.6% -$58.3K 0.35% 61
2024
Q1 		$9.61M Sell
2,992,563
-58,121
-2% -$225K 0.31% 64
2023
Q4 		$14.9M Sell
3,050,684
-7,522
-0.2% -$34.3K 0.53% 54
2023
Q3 		$16.7M Sell
3,058,206
-46,755
-2% -$309K 0.67% 51
2023
Q2 		$20.8M Buy
3,104,961
+1,197,872
+63% +$8.91M 0.78% 44
2023
Q1 		$16.8M Buy
1,907,089
+26,522
+1% +$234K 0.87% 42
2022
Q4 		$14.4M Sell
1,880,567
-13,828
-0.7% -$108K 0.8% 44
2022
Q3 		$13.5M Buy
1,894,395
+565,127
+43% +$5.32M 0.82% 42
2022
Q2 		$10.8M Buy
1,329,268
+569,856
+75% +$5.01M 0.83% 35
2022
Q1 		$10.5M Buy
759,412
+13,617
+2% +$214K 0.65% 38
2021
Q4 		$20.9M Buy
745,795
+18,461
+3% +$566K 1.21% 28
2021
Q3 		$24.7M Buy
727,334
+9,684
+1% +$350K 1.64% 22
2021
Q2 		$29.3M Buy
717,650
+146,708
+26% +$5.7M 1.93% 18
2021
Q1 		$23M Buy
570,942
+22,562
+4% +$1.22M 1.68% 23
2020
Q4 		$32.4M Buy
548,380
+17,235
+3% +$889K 2.5% 10
2020
Q3 		$25.8M Buy
531,145
+19,413
+4% +$816K 2.28% 15
2020
Q2 		$24.8M Buy
511,732
+140,891
+38% +$5.14M 2.38% 12
2020
Q1 		$10.3M Buy
370,841
+7,232
+2% +$202K 1.57% 26
2019
Q4 		$10.9M Buy
363,609
+313,150
+621% +$8.99M 1.39% 28
2019
Q3 		$1.56M Buy
+50,459
New +$2.06M 0.45% 46

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aristotle Atlantic Partners's ADPT Position: Q2 2026 in Review

Aristotle Atlantic Partners increased its Adaptive Biotechnologies (ADPT) stake by 7.2% in Q2 2026, buying an estimated $1.9M and bringing the position to 1,838,513 shares worth $39.4M. The position accounts for 1.64% of the portfolio, ranked #17.

Aristotle Atlantic Partners first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $46.8M in Q3 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Aristotle Atlantic Partners held 1,838,513 shares of Adaptive Biotechnologies worth $39.4M as of Q2 2026.
  • Aristotle Atlantic Partners bought 124,167 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.9M.
  • Adaptive Biotechnologies made up 1.64% of Aristotle Atlantic Partners's portfolio in Q2 2026, its #17 holding.
  • Aristotle Atlantic Partners first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • Aristotle Atlantic Partners's Adaptive Biotechnologies position peaked at $46.8M in Q3 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2026, filed 14 Aug 2026.